Entity

Time filter

Source Type

Trowbridge, United Kingdom

Stepanova M.,George Mason University | Stepanova M.,Health Integrated | Rodriguez E.,George Mason University | Birerdinc A.,George Mason University | And 4 more authors.
Oncotarget | Year: 2015

Aging is associated with an increase in a chronic, low-grade inflammation. This phenomenon, termed "inflammaging" is also a risk factor for both morbidity and mortality in the elderly. Frequent co-occurrence of chronic diseases, known as multi-morbidity, may be explained by interconnected pathophysiology of these conditions, most of which depend on its inflammatory component. Here we present an analysis of the U.S. National Health and Nutrition Examination Survey data collected between 1999 and 2008, for the presence, and the number, of chronic diseases along with HDL-cholesterol, C-reactive protein, white blood cell count, lymphocyte percent, monocyte percent, segmented neutrophils percent, eosinophils percent, basophils percent, and glycohemoglobin levels. Importantly, even after adjustment for age and BMI, many inflammatory markers continued to be associated to multi-morbidity. C-reactive protein (CRP) levels and Glasgow Prognostic Score (GPS) were most dramatically increased in parallel with an accumulation of chronic diseases, and may be utilized as multi-morbidity predictors. These observations point at background inflammation as direct, age-independent contributor to an accumulation of the disease burden. Our findings also suggest a possibility that systemic inflammation associated with chronic diseases may explain accelerated aging phenomenon previously observed among the patients with heavy disease burden. Source


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Small Business Research Initiative | Award Amount: 149.91K | Year: 2016

A Rapid Stratified Medicine Diagnostic Test To Direct Treatment For Symptomatic Patients Presenting In Sexual Health Clinics Atlas Genetics will develop a rapid point-of-care (PoC) stratified medicine diagnostic (SMD) for patients presenting to Sexual Health Clinics with genital discharge syndrome, to allow immediate and accurate selection of appropriate and effective antibiotic treatment. The development and design of the diagnostic will be supported by validated cost-effectiveness modelling of introducing this multi-pathogen PoC-SMD test as well as a study on its potential patient impact. This supporting work will be carried out by the Applied Diagnostic Research and Evaluation Unit (ADREU) at St George’s, University of London (SGUL) in collaboration with Aquarius Population Health. In addition, preliminary work will build on the experience established at Atlas in the implementation of multiplex assays on the io™ Point Of Care platform to assess the challenges involved in expanding multiplexing to include at least four pathogens on a single rapid testing cartridge required for implementation of the proposed stratified medicine diagnostics. At the end of Phase 1, the value to the NHS of a SMD in sexual health will become apparent and the technical path will be established for development and evaluation in Phase 2.


Patent
Atlas Genetics | Date: 2015-09-04

The invention provides a method of probing for a nucleic acid comprising: contacting a nucleic acid solution with an oligonucleotide probe labelled with an electrochemically active marker, providing conditions at which the probe is able to at least partially hybridise with any complementary target sequence which may be present in the nucleic acid solution, selectively degrading either hybridised, partially hybridised or unhybridised nucleic acid probe, and electrochemically determining information relating to the electrochemically active marker. The invention further provides novel molecules with use in methods of the invention.


The invention provides a method of probing for a nucleic acid comprising: contacting a nucleic acid solution with an oligonucleotide probe labelled with an electrochemically active marker, providing conditions at which the probe is able to at least partially hybridise with any complementary target sequence which may be present in the nucleic acid solution, selectively degrading either hybridised, partially hybridised or unhybridised nucleic acid probe, and electrochemically determining information relating to the electrochemically active marker. The invention further provides novel molecules with use in methods of the invention.


Patent
Atlas Genetics | Date: 2015-08-05

The invention provides a method of probing for a nucleic acid comprising: contacting a nucleic acid solution with an oligonucleotide probe labelled with an electrochemically active marker, providing conditions at which the probe is able to at least partially hybridise with any complementary target sequence which may be present in the nucleic acid solution, selectively degrading either hybridised, partially hybridised or unhybridised nucleic acid probe, and electrochemically determining information relating to the electrochemically active marker. The invention further provides novel molecules with use in methods of the invention.

Discover hidden collaborations